Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and thank you all for participating in today's call. Joining me today is Puneet Dhillon, Sky's President and CEO, Chris Twitty, CSO, and Caitlin Arsenault, Sky's CFO. Before we begin, I'd like to caution that comments made during this conference call will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Sky's expectations regarding its development activities, timelines, and milestones. forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statements made today. I encourage you to review all the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Puneet Gillan. Good afternoon and thank you for joining us. I'm here with members of our management team to review Sky's first quarter 2025 performance. I'll briefly recap our key upcoming clinical milestones and highlight our operational roadmap for the rest of 2025 before turning it over to our CSO and CFO to share more details around our preclinical data and financials. We delivered meaningful scientific, clinical, and operational progress this quarter. Most notably, we completed enrollment in our Phase 2a CBON trial ahead of schedule. We've now moved forward with an amendment to extend the study to 52 weeks. This positions us to collect longer-term data on safety, tolerability, and efficacy, both as monotherapy and in combination with GLP-1. La...